Minerva Neurosciences | NERV - Stammkapital





Stammkapital Veränderung Datum
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Adma Biologics USD 237.88M 457K 2025-12
ALKERMES USD 165.61M 503K 2025-12
Alterity Therapeutics Limited AUD 213.97M 144.39K 2023-06
AstraZeneca USD 1.55B 206K 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cipla INR 807.77M 807.43M 2025-09
Clal Biotechnology ILS 1.61M 0 2022-12
Compugen USD 94.55M 1.02M 2025-12
CSL USD 482.13M 93.87M 2025-12
Eli Lilly USD 946.83M 354.23M 2025-06
Esperion Therapeutics USD 245.22M 39.79M 2025-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Grifols EUR 680.58M 846.11K 2025-12
Halozyme Therapeutics USD 117.78M 259K 2025-12
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
J&J USD 2.41B 584K 2025-09
Merck USD 2.49B 15.79M 2025-09
Minerva Neurosciences USD 1000 0 2024-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.91B 10.64M 2025-12
Novavax USD 162.58M 106K 2025-12
Pfizer USD 5.69B 1000K 2025-09
Roche Holding CHF 795.62M 699.54K 2025-12
Takeda JPY 1.58B 2K 2025-12
Vanda Pharmaceuticals USD 58K 0 2024-12